Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Unedo Hence Markus, Sihombing"'
Autor:
Unedo Hence Markus Sihombing, Andrijono Andrijono, Gatot Purwoto, Supriadi Gandamihardja, Alida R. Harahap, Primariadewi Rustamadji, Aria Kekalih, Retno Widyawati, Dzicky Rifqi Fuady
Publikováno v:
Journal of the Egyptian National Cancer Institute, Vol 34, Iss 1, Pp 1-9 (2022)
Abstract Background The conventional standard treatment for ovarian cancer is not very effective, and the disease is fatal for women. Cancer Stem Cells (CSCs) that express CD44+/CD24- can contribute to chemoresistance and a poor prognosis. We seek to
Externí odkaz:
https://doaj.org/article/95eb48f1add6407799bae8d73088b8a2
Autor:
Unedo Hence Markus Sihombing, Andrijono, Gatot Purwoto, Supriadi Gandamihardja, Alida R. Harahap, Primariadewi Rustamadji, Aria Kekalih, Retno Widyawati, Dzicky Rifqi Fuady
Publikováno v:
Gynecologic Oncology Reports, Vol 42, Iss , Pp 101005- (2022)
Backgrounds: Ovarian cancer is the 8th deadliest common cancer in women around the world. Almost all ovarian cancer patients would experience chemoresistance, recurrence, and poor prognosis after cytoreductive surgery and platinum-based chemotherapy.
Externí odkaz:
https://doaj.org/article/1f08aeff8d154221869a77dda933f830
Autor:
Unedo Hence Markus Sihombing, Andrijono Andrijono, Gatot Purwoto, Supriadi Gandamihardja, Alida R. Harahap, Primariadewi Rustamadji, Aria Kekalih, Retno Widyawati, Dzicky Rifqi Fuady
Ovarian cancer is one of the deadliest women’s cancers. There is much chemoresistance to ovarian cancer standard therapy. CD44+/CD24− have an essential role in developing chemoresistance and poor prognosis for the patients. We aimed to study CD44
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70a99cc3a0c3bf35eded0df7f4feb4c2
https://doi.org/10.21203/rs.3.rs-1459958/v2
https://doi.org/10.21203/rs.3.rs-1459958/v2
Autor:
Unedo Hence Markus, Sihombing, Andrijono, Gatot, Purwoto, Supriadi, Gandamihardja, Alida R, Harahap, Primariadewi, Rustamadji, Aria, Kekalih, Retno, Widyawati, Dzicky Rifqi, Fuady
Publikováno v:
Gynecologic oncology reports. 42
Ovarian cancer is the 8th deadliest common cancer in women around the world. Almost all ovarian cancer patients would experience chemoresistance, recurrence, and poor prognosis after cytoreductive surgery and platinum-based chemotherapy. Chemoresista
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ec34d01d0c539e13513fab6d31bddde4
https://pubmed.ncbi.nlm.nih.gov/35707599
https://pubmed.ncbi.nlm.nih.gov/35707599
Autor:
Unedo Hence Markus Sihombing, Andrijono Andrijono, Gatot Purwoto, Supriadi Gandamihardja, Alida R. Harahap, Primariadewi Rustamadji, Aria Kekalih, Retno Widyawati, Dzicky Rifqi Fuady
Objective: Ovarian cancer is the 8th deadliest women’s cancer in the world. Almost all patients experienced chemoresistance, recurrence, and poor prognosis after cytoreductive surgery followed by platinum-based chemotherapy. Chemoresistant cancer c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e6edfda7139aa6b833222d754facbb0d
https://doi.org/10.21203/rs.3.rs-1440070/v2
https://doi.org/10.21203/rs.3.rs-1440070/v2
Autor:
Unedo Hence Markus Sihombing, Andrijono Andrijono, Gatot Purwoto, Supriadi Gandamihardja, Alida R. Harahap, Primariadewi Rustamadji, Aria Kekalih, Dzicky Rifqi Fuady
Objective: Ovarian cancer is the 8th deadliest women’s cancer in the world. In 2018 there were 295.414 new cases with 184.799 deaths. In Indonesia, there are 13.310 (7,1%) ovarian cancer of 188.231 female cancer with an incidence of 9,7/100,000. Al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3adc0abb65f1ce00fbc09d0ea1049cd8
https://doi.org/10.21203/rs.3.rs-1440070/v1
https://doi.org/10.21203/rs.3.rs-1440070/v1